# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 Assignment ID: PATI775014

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
DONALD G. STEIN	05/12/2023
DAVID BRIAN GUTHRIE	06/09/2023
DENNIS C. LIOTTA	09/08/2022

### **RECEIVING PARTY DATA**

Company Name:	EMORY UNIVERSITY
Street Address:	1599 CLIFTON ROAD NE, 4TH FLOOR
City:	Atlanta
State/Country:	GEORGIA
Postal Code:	30322

### **PROPERTY NUMBERS Total: 6**

Property Type	Number
Application Number:	61864681
PCT Number:	US1450565
Application Number:	14911807
Application Number:	18211816
Application Number:	15728459
Application Number:	16599892

#### **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (404)815-6500

Email: cbyrd@ktslaw.com

Correspondent Name: Chenae Monique Byrd

Address Line 1: KILPATRICK TOWNSEND & STOCKTON LLP

**Address Line 2:** 1100 Peachtree Street NE, Suite 2800

Address Line 4: Atlanta, GEORGIA 30309

ATTORNEY DOCKET NUMBER:	043150-1388964 (Family)
NAME OF SUBMITTER:	Chenae Byrd
SIGNATURE:	/Chenae Byrd/

Total Attachments: 5
source=EMY-050US50US5 Assignment-Parent-ALL 043150-1388964#page1.tiff
source=EMY-050US50US5 Assignment-Parent-ALL 043150-1388964#page2.tiff
source=EMY-050US50US5 Assignment-Parent-ALL 043150-1388964#page3.tiff
source=EMY-050US50US5 Assignment-Parent-ALL 043150-1388964#page4.tiff
source=EMY-050US50US5 Assignment-Parent-ALL 043150-1388964#page5.tiff

# ASSIGNMENT

(Patent Application)

We, David Brian Guthrie, Mark Andrew Lockwood, Michael G. Natchus, Dennis C. Liotta, Donald G. Stein, and Iqbal Sayced, have invented certain inventions and improvements disclosed in a patent application entitled

"PROGESTERONE PHOSPHATE ANALOGS AND USES RELATED THERETO,"

filed in the United States Patent and Trademark Office as U.S. Patent Application No. 17/360,614 filed on June 28, 2021; which is a continuation of U.S. Patent Application No. 16/599,892 filed on October 11, 2019, now issued U.S. Patent No. 11,053,276; which is a continuation of U.S. Patent Application No. 15/728,459 filed on October 9, 2017, now issued U.S. Patent No. 10/487,109; which is a continuation of U.S. Patent Application No. 14/911,807 filed on February 12, 2016, now issued U.S. Patent No. 9,802,978; which is a U.S. national stage of International Patent Application No. PCT/US2014/050565 filed on August 11, 2014; which claims benefit of U.S. Provisional Patent Application No. 61/864,681 filed on August 12, 2013.

NOW, THEREFORE, consistent with our existing obligations under the Intellectual Property Policy laid out in Section 7.6 of the Emory University Policy Manual, for good and valuable consideration received the sufficiency and adequacy of which are hereby acknowledged, we, David Brian Guthrie, Mark Andrew Lockwood, Michael G. Natchus, Dennis C. Liotta, Donald G. Stein, and Iqbal Sayeed:

- Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Emory University, a University having a principal place of business at 1599 Clifton Road, 4th Floor, Atlanta, Georgia 30322 ("Assignee"), our entire right, title, and interest in and to:
  - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
  - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
  - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and

- (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
- (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignce's own use.
- Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S.
  agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting
  from the intellectual property, patent application(s) and patents described in paragraph 1 of
  this Assignment.
- 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
- 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignce, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
- 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Date: 06/09/2023	Dallo Hum	
	David Brian Guthric	
WITNESSED BY:		
Name:	Date: 06/09/2023	Luke Keller
Name: Sini Panirku	Date: 06.09.2023	SINI PANICKER
Date:		
	Mark Andrew Lockwood	
WITNESSED BY:		
Name:	Date:	
Name:	Date:	***************************************
Date:		
	Michael G. Natchus	
WITNESSED BY:		
Name:	Date:	
Name	Date:	

Date: 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Dennis C. Liotta
Name: Via fers (2007) Name: Via fers (2007)	Date:
Date: WITNESSED BY:	Donald G. Stein
Name:	Date:
Name:	Date:
Date:	Iqbal Sayeed
WITNESSED BY:	
Name:	Date:
Name:	Date:

PATENT REEL: 069973 FRAME: 0065

**RECORDED: 08/07/2023** 

Date	Dennis C. Llotta
WITNESSED BY	
Name	Date:
Name	Date:
Date: May 12 2023 WITNESSED BY Mame: Mame: Name:	Donald G. Stein $\frac{5/12/23}{\text{Date:}}$ Date:
Date:	Iqbal Sayced
WITNESSED BY:	
Name:	Date:
Name:	Date:

PATENT REEL: 069973 FRAME: 0066

RECORDED: 06/29/2025